HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study
Journal of the International AIDS Society · 2024-05 · 27 (5)
DOI: 10.1002/jia2.26252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the International AIDS Society, online erschienen am 23.05.2024. Verfasst von Christina Psaros und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Anti-HIV Agents, Drug Monitoring. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HPTN Statistical and Data Management Center, National Institute of Allergy and Infectious Diseases, NIMH NIH HHS.
Abstract (Originalsprache)
Introduction
HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre‐exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial.
Methods
Participants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews ( N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent ( n = 27), non‐adherent ( n = 12) and early discontinuers ( n = 1). Data were organized using NVivo software and analysed using content analysis.
Results
Participants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study‐related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non‐judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection‐related anxiety, which abated with time and when given some measure of control (e.g. pre‐injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules).
Conclusions
Respondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non‐judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Behavioral, Social and Health Education Sciences, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
- AstraZeneca Pharmaceuticals, Chicago, Illinois, USA.
ORCID-Profile: Christina Psaros, Georgia R Goodman, Whitney Rice, Colleen F Kelley, Lara E Coelho, Nittaya Phanuphak, Jesse Clark, Jeremy Sugarman, Steven A Safren
Förderung
- HPTN Statistical and Data Management Center
- National Institute of Allergy and Infectious Diseases
- NIMH NIH HHS
- NIAID NIH HHS
- NIH HHS
- HIV Prevention Trials Network
- NIDA NIH HHS
- Eunice Kennedy Shriver Institute for Child Health and Human Development
Zitieren
APA
Psaros, C., Goodman, G. R., Lee, J. S., Rice, W., Kelley, C. F., Oyedele, T., Coelho, L. E., Phanuphak, N., Singh, Y., Middelkoop, K., Griffith, S., McCauley, M., Rooney, J., Rinehart, A. R., Clark, J., Go, V., Sugarman, J., Fields, S. D., Adeyeye, A., …, & HPTN 083‐02 Study Team (2024). HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study. Journal of the International AIDS Society, 27(5). https://doi.org/10.1002/jia2.26252
Vancouver
Psaros C, Goodman GR, Lee JS, Rice W, Kelley CF, Oyedele T, et al. HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study. Journal of the International AIDS Society. 2024;27(5). doi:10.1002/jia2.26252
BibTeX
@article{Psaros2024,
author = {Psaros, Christina and Goodman, Georgia R and Lee, Jasper S and Rice, Whitney and Kelley, Colleen F and Oyedele, Temitope and Coelho, Lara E and Phanuphak, Nittaya and Singh, Yashna and Middelkoop, Keren and Griffith, Sam and McCauley, Marybeth and Rooney, James and Rinehart, Alex R and Clark, Jesse and Go, Vivian and Sugarman, Jeremy and Fields, Sheldon D and Adeyeye, Adeola and Grinsztejn, Beatriz and Landovitz, Raphael J and Safren, Steven A and HPTN 083‐02 Study Team, HPTN 083‐02 Study Team},
title = {HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study},
journal = {Journal of the International AIDS Society},
year = {2024},
volume = {27},
number = {5},
doi = {10.1002/jia2.26252}
}
EUVIMED